Table 2. Association between 6MWD and time to all-cause death up to end of study.
| 6MWD assessment | Categorization | Number of deaths (all-cause) / number of patients | Unadjusted hazard ratio (95% CI) (vs. reference) | Adjusteda hazard ratio (95% CI) (vs. reference) |
|---|---|---|---|---|
| Month 6 | ≤400 m; reference | 53/325 | – | – |
| >400 m | 22/300 | 0.45 (0.27–0.74) | 0.45 (0.26–0.78) | |
| Q1 (≤339 m; reference) | 34/157 | – | – | |
| Q2 (>339−≤397 m) | 19/158 | 0.53 (0.30–0.93) | 0.49 (0.28–0.89) | |
| Q3 (>397−≤452 m) | 13/154 | 0.38 (0.20–0.71) | 0.34 (0.17–0.68) | |
| Q4 (>452 m) | 9/156 | 0.27 (0.13–0.55) | 0.24 (0.11–0.53) | |
| Baseline | Q1 (≤300 m; reference) | 62/197 | – | – |
| Q2 (>300−≤372 m) | 31/179 | 0.50 (0.33–0.77) | 0.56 (0.36–0.88) | |
| Q3 (>372−≤430 m) | 22/182 | 0.35 (0.21–0.56) | 0.36 (0.21–0.60) | |
| Q4 (>430 m) | 11/181 | 0.18 (0.09–0.34) | 0.18 (0.09–0.37) | |
| Change from baseline to Month 6 | Q1 (≤–10 m; reference) | 16/160 | – | – |
| Q2 (≥–10−≤19 m) | 18/157 | 1.11 (0.56–2.17) | 1.10 (0.56–2.18) | |
| Q3 (>19−≤55 m) | 18/153 | 1.13 (0.58–2.22) | 0.97 (0.49–1.92) | |
| Q4 (>55 m) | 23/155 | 1.41 (0.75–2.68) | 1.19 (0.62–2.29) |
aAdjusted for study treatment, use of background PAH therapy at baseline, age, sex, PAH etiology, and WHO FC.
6MWD, six-minute walk distance; CI, confidence interval; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization functional class.